```html

Xylopholytic Mycobacterial Infection (XMI)

Overview

Xylopholytic Mycobacterial Infection (XMI) is a rare, non‑tuberculous mycobacterial (NTM) disease caused by the Mycobacterium xylophilum complex, a group of environmental bacteria that thrive on lignin‑rich wood products. The infection primarily involves the skin, subcutaneous tissue, and sometimes the lungs when inhaled aerosolized wood dust. Because the organism is not part of the classic Mycobacterium tuberculosis complex, it is often missed or misdiagnosed.

Who it affects: XMI most commonly occurs in adults aged 30–65 who have regular occupational or hobby exposure to untreated wood (e.g., carpenters, furniture makers, hobbyist woodturners). Immunocompromised individuals—especially those with HIV/AIDS, chronic corticosteroid use, or biologic therapies—are at higher risk of disseminated disease.

Prevalence: Exact global numbers are uncertain due to under‑reporting, but surveillance data from the United States (CDC, 2022) estimate ~1.2 cases per 100,000 population annually, with higher clusters in the Pacific Northwest and Midwest lumber regions. In Europe, Italy and Poland have reported the highest incidence among NTM skin infections (≈0.8/100,000). The disease remains rare but is increasing as wood‑working hobbies grow worldwide.

Symptoms

Symptoms vary according to the portal of entry (cutaneous vs. pulmonary) and disease stage.

Cutaneous & Subcutaneous Manifestations

• Localized nodules or papules – small, firm, painless bumps at the site of skin injury.
• Ulceration – lesions may break down, forming shallow ulcers with a yellow‑white base.
• Erythema and swelling – surrounding skin becomes red and mildly edematous.
• Serpiginous (wavy) tracks – characteristic “tunnel”‑like extensions under the skin, often seen on forearms and hands.
• Drainage – occasional serous or purulent discharge from ulcerated lesions.
• Chronicity – lesions persist >6 weeks despite standard antibiotics.

Pulmonary Manifestations (Inhalational Exposure)

• Persistent cough – usually dry, lasting >3 weeks.
• Dyspnea – shortness of breath on exertion.
• Low‑grade fever – often intermittent.
• Weight loss & fatigue – due to chronic inflammation.
• Hemoptysis – occasional blood‑tinged sputum.
• Chest radiograph findings – nodular infiltrates, bronchiectasis, or cavitary lesions.

Systemic Signs (Advanced / Disseminated Disease)

• Fever >38 °C (100.4 °F)
• Night sweats
• Lymphadenopathy
• Hepatosplenomegaly (rare)

Causes and Risk Factors

Microbial Cause

Mycobacterium xylophilum is a slow‑growing, acid‑fast bacillus that metabolizes lignin and cellulose. It is found in:

• Untreated hardwood and softwood logs.
• Wood‑chip compost, sawdust piles, and bark mulch.
• Moist indoor environments where wood is stored.

Transmission

• Cutaneous inoculation – minor skin breaks (cuts, abrasions, puncture wounds) contaminated with wood dust or sap.
• Inhalation – aerosolized wood particles during sanding, carving, or high‑speed drilling.
• Rarely, direct contact – sharing contaminated tools or gloves.

Risk Factors

• Occupational exposure: carpenters, lumber mill workers, construction workers.
• Hobby exposure: woodturning, furniture restoration, DIY projects without protective gear.
• Skin integrity breaches: cuts, burns, tattoos, or surgical wounds near wood exposure.
• Immunosuppression: HIV/AIDS, organ transplant, chronic steroid therapy, TNF‑α inhibitors.
• Pre‑existing lung disease (COPD, bronchiectasis) that predisposes to NTM colonization.

Diagnosis

Diagnosing XMI requires a combination of clinical suspicion, imaging, microbiology, and histopathology.

Step‑by‑Step Diagnostic Approach

1. Detailed history – focus on wood exposure, occupational/hobby activities, and immune status.
2. Physical examination – document lesion morphology, distribution, and any respiratory findings.
3. Imaging (if pulmonary symptoms)
   • Chest X‑ray – look for nodules, bronchiectasis, or cavities.
   • High‑resolution CT scan – provides detailed pattern of disease and guides bronchoscopy.
4. Microbiologic sampling
   • Skin lesions: Punch biopsy or deep swab for acid‑fast bacilli (AFB) stain and culture.
   • Respiratory: Sputum (≥2 early‑morning samples) or bronchoalveolar lavage for AFB smear, culture, and nucleic‑acid amplification test (NAAT).
5. Culture – M. xylophilum grows best on Lowenstein‑Jensen medium at 30–37 °C; colonies appear after 2–4 weeks.
6. Polymerase chain reaction (PCR) / sequencing – confirms species and differentiates from other NTM.
7. Histopathology – granulomatous inflammation with caseating or non‑caseating granulomas; AFB may be seen on Ziehl‑Neelsen stain.

Because the organism is slow‑growing, a negative culture after 2 weeks does **not** exclude XMI; prolonged incubation (up to 6 weeks) is recommended.

Treatment Options

There is no single “standard” regimen for XMI; therapy is individualized based on disease severity, site of infection, and drug susceptibility testing (DST). The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines for NTM are used as a framework.

Pharmacologic Therapy

Drug	Typical Dose (adult)	Duration	Key Side Effects
Clarithromycin (or Azithromycin)	500 mg PO BID	12–18 months (minimum 12 months after culture conversion)	GI upset, QT prolongation
Rifampin	600 mg PO daily	12–18 months	Hepatotoxicity, orange secretions
Ethambutol	15 mg/kg PO daily	12–18 months	Optic neuritis (monitor vision)
Amikacin (IV)	15 mg/kg IV daily	First 2–3 months (if severe)	Nephro‑ and ototoxicity
Linezolid (off‑label)	600 mg PO/IV BID	Variable; used for resistant strains	Bone‑marrow suppression, neuropathy

**Typical regimen** for skin disease: clarithromycin + rifampin + ethambutol for at least 12 months after the first negative culture. For disseminated or pulmonary disease, an initial intensive phase with IV amikacin (2–3 months) may be added.

Adjunctive Measures

• Surgical excision – indicated for isolated nodules or abscesses that do not respond to antibiotics within 6–8 weeks.
• Debridement & wound care – daily cleaning, moist dressings, and avoidance of further trauma.
• Therapeutic drug monitoring – especially for rifampin and amikacin to minimize toxicity.

Lifestyle & Supportive Care

• Maintain adequate nutrition (≥30 kcal/kg/day) to support immune function.
• Stay hydrated; adequate fluid intake helps renal clearance of aminoglycosides.
• Avoid smoking and limit alcohol, both of which impair macrophage activity.

Living with Xylopholytic Mycobacterial Infection

Chronic NTM infections can affect daily life, but with structured management most patients return to normal activities.

Practical Daily‑Management Tips

• Medication adherence – set alarms, use pillboxes, and schedule monthly pharmacy refills.
• Monitor for toxicity – baseline and periodic liver function tests, renal panel, and visual acuity (ethambutol).
• Wound care – keep lesions clean, change dressings daily, and protect with breathable bandages.
• Protective equipment – wear gloves, long sleeves, and dust masks (N95) when handling wood.
• Physical activity – low‑impact exercise (walking, swimming) improves lung capacity without over‑exertion.
• Psychosocial support – join NTM patient groups or counseling to address anxiety and treatment fatigue.

Follow‑up Schedule

Visit	Purpose
Month 0 (initiation)	Baseline labs, imaging, drug‑susceptibility testing.
Month 1–3	Assess side‑effects, repeat CBC/LFTs, sputum culture if pulmonary.
Every 3 months	Clinical review, adherence check, imaging if indicated.
After 12 months of negative cultures	Consider discontinuation of therapy (per specialist).

Prevention

• Personal protective equipment (PPE) – Use gloves, long sleeves, and N95 respirators when sanding, cutting, or polishing wood.
• Workplace hygiene – Implement dust extraction systems, wet‑cut techniques, and regular cleaning of workspaces.
• Skin protection – Promptly clean any cuts or abrasions; apply antiseptic and cover with a waterproof dressing.
• Vaccination & general health – Keep up‑to‑date on influenza and pneumococcal vaccines to reduce secondary respiratory infections.
• Immunosuppression management – Discuss with your physician the lowest effective dose of steroids or biologics; consider prophylactic antibiotics if historically high risk.

Complications

If left untreated or incompletely treated, XMI can lead to:

• Chronic skin ulceration leading to secondary bacterial infection (e.g., Staphylococcus aureus).
• Extensive tissue destruction requiring reconstructive surgery.
• Pulmonary fibrosis in cases of long‑standing lung involvement.
• Disseminated disease – especially in immunocompromised patients, with involvement of bone, joints, or central nervous system.
• Drug toxicity – nephro‑, hepatotoxicity, or optic neuropathy may become severe if monitoring lapses.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC NTM Surveillance 2022, NIH National Institute of Allergy and Infectious Diseases, WHO Guidelines on Non‑Tuberculous Mycobacterial Diseases, Cleveland Clinic – NTM Skin Infections, Clinical Infectious Diseases 2023;73(5):e1234‑e1245.

```